Double maintains 2 strategies that include COLL - Collegium Pharmaceutical, Inc.
Current Value
$32.571 Year Return
Current Value
$32.571 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HIMX | -0.03% | $1.64B | +14.25% | 3.93% |
| SOL | -0.06% | $98.02M | +6.70% | 0.00% |
| APP | -0.07% | $113.39B | +294.89% | 0.00% |
| DNB | 0.08% | $4.07B | -8.26% | 1.65% |
| BE | -0.09% | $5.90B | +81.82% | 0.00% |
| CME | -0.10% | $99.13B | +45.75% | 1.74% |
| EDN | -0.15% | $549.00M | +45.89% | 0.00% |
| NNE | -0.16% | $1.42B | +36.88% | 0.00% |
| UUU | 0.19% | $7.70M | +126.53% | 0.00% |
| CCEC | 0.34% | $1.02B | +3.91% | 2.46% |
| SEZL | 0.40% | $4.48B | +823.02% | 0.00% |
| T | 0.40% | $194.07B | +43.38% | 4.08% |
| PLTR | 0.41% | $335.34B | +406.23% | 0.00% |
| KR | 0.43% | $46.66B | +34.46% | 1.80% |
| MELI | 0.47% | $121.04B | +35.56% | 0.00% |
| BBDO | -0.48% | $13.44B | +24.32% | 3.28% |
| CRIS | -0.58% | $21.96M | -73.63% | 0.00% |
| XOS | -0.59% | $28.59M | -47.88% | 0.00% |
| PPC | 0.63% | $10.68B | +33.54% | 0.00% |
| SAVA | 0.71% | $102.90M | -81.49% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -27.83% | $94.90M | 0.59% |
| VIXY | -26.53% | $200.94M | 0.85% |
| VIXM | -22.35% | $22.99M | 0.85% |
| FTSD | -21.87% | $233.24M | 0.25% |
| IVOL | -21.84% | $341.06M | 1.02% |
| TBLL | -18.50% | $2.12B | 0.08% |
| BTAL | -17.42% | $310.24M | 1.43% |
| XONE | -15.94% | $629.16M | 0.03% |
| SHYM | -15.31% | $355.87M | 0.35% |
| SPTS | -14.53% | $5.78B | 0.03% |
| IBTG | -14.50% | $1.93B | 0.07% |
| FXY | -13.98% | $798.58M | 0.4% |
| SCHO | -13.83% | $10.92B | 0.03% |
| WEAT | -13.83% | $124.92M | 0.28% |
| IBTH | -13.74% | $1.62B | 0.07% |
| IBTF | -13.71% | $1.98B | 0.07% |
| BSMW | -13.53% | $107.58M | 0.18% |
| CORN | -13.22% | $43.88M | 0.2% |
| CGSM | -13.07% | $725.21M | 0.25% |
| VGSH | -12.17% | $22.70B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GOVT | 0.07% | $27.40B | 0.05% |
| IBMR | -0.08% | $258.41M | 0.18% |
| TFLO | -0.08% | $6.73B | 0.15% |
| PHDG | 0.08% | $87.21M | 0.39% |
| MEAR | 0.10% | $1.14B | 0.25% |
| OWNS | -0.16% | $128.82M | 0.3% |
| JPST | -0.17% | $32.02B | 0.18% |
| IBTP | -0.18% | $143.68M | 0.07% |
| BNDW | 0.22% | $1.29B | 0.05% |
| KCCA | -0.25% | $109.01M | 0.87% |
| JUCY | -0.30% | $256.84M | 0.6% |
| TDTT | -0.32% | $2.63B | 0.18% |
| STIP | -0.39% | $12.73B | 0.03% |
| SHYD | -0.39% | $332.11M | 0.35% |
| NUBD | -0.40% | $397.19M | 0.16% |
| TOTL | -0.42% | $3.81B | 0.55% |
| TIPX | 0.43% | $1.74B | 0.15% |
| FLIA | 0.50% | $706.55M | 0.25% |
| ICSH | -0.51% | $5.96B | 0.08% |
| CMF | -0.63% | $3.50B | 0.08% |
Yahoo
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expi
Finnhub
Collegium Pharmaceutical, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $150 million worth of its own shares. The company to utilize existing cash on...
Yahoo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is one of the 12 Small Cap Stocks with High Upside Potential. On May 12, the diversified biopharmaceutical company entered an accelerated share purchase agreement with Jefferies LLC. Under the agreement, the company agreed to repurchase $25 million of the company’s common stock. The accelerated share repurchase program is part of […]
SeekingAlpha
Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug
Yahoo
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...
Yahoo
Collegium Pharmaceutical’s first quarter results were well received by the market, with management crediting growth in its ADHD medicine Jornay and stability in its pain portfolio as the primary drivers. CEO Vikram Karnani highlighted that Jornay prescriptions grew 24% year-over-year, and all three pain medicines delivered single-digit revenue growth, despite typical first-quarter headwinds. Karnani emphasized, “We have made significant progress on each of our strategic priorities,” citing the s
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SCL | 43.69% | $1.33B | -32.66% | 2.61% |
| MTD | 42.83% | $25.44B | -9.95% | 0.00% |
| CPRX | 42.77% | $2.66B | +31.54% | 0.00% |
| FOXF | 42.64% | $1.21B | -41.04% | 0.00% |
| LGIH | 42.50% | $1.28B | -45.58% | 0.00% |
| PLOW | 41.68% | $704.87M | +34.14% | 3.90% |
| IQV | 41.67% | $28.16B | -27.38% | 0.00% |
| BBSI | 41.64% | $1.11B | +29.20% | 0.75% |
| SANA | 41.49% | $942.82M | -29.75% | 0.00% |
| MSM | 41.20% | $5.03B | +13.94% | 3.77% |
| BFS | 40.97% | $848.27M | -9.20% | 6.77% |
| NNI | 40.70% | $4.43B | +14.72% | 0.92% |
| SWK | 40.53% | $11.27B | -17.58% | 4.55% |
| IVT | 40.44% | $2.11B | +5.77% | 3.44% |
| JOE | 39.97% | $3.01B | -10.80% | 1.08% |
| APAM | 39.60% | $3.30B | +13.43% | 6.53% |
| VIR | 39.50% | $781.04M | -39.70% | 0.00% |
| HNI | 39.29% | $2.40B | +8.67% | 2.58% |
| TXT | 39.21% | $15.35B | -4.25% | 0.09% |
| FUL | 39.11% | $3.41B | -23.74% | 1.44% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -15.44% | $47.31M | +7.56% | 0.00% |
| K | -14.39% | $27.56B | +40.50% | 2.87% |
| LITB | -12.47% | $24.09M | -72.65% | 0.00% |
| RCEL | -10.63% | $141.60M | -39.10% | 0.00% |
| VSTA | -10.17% | $324.82M | +33.88% | 0.00% |
| QBTS | -9.62% | $4.63B | +1,123.97% | 0.00% |
| IONQ | -9.04% | $10.94B | +394.79% | 0.00% |
| QXO | -8.54% | $14.19B | -57.24% | 0.00% |
| DG | -8.40% | $24.90B | -14.56% | 2.08% |
| API | -7.67% | $282.97M | +49.02% | 0.00% |
| INOD | -7.67% | $1.58B | +193.82% | 0.00% |
| SRRK | -7.41% | $3.55B | +311.43% | 0.00% |
| FATBB | -7.38% | $47.23M | -10.96% | 10.49% |
| DFDV | -6.81% | $401.69M | +2,774.82% | 0.00% |
| DAO | -6.55% | $274.33M | +135.75% | 0.00% |
| BTCT | -6.52% | $31.95M | +108.85% | 0.00% |
| PULM | -5.71% | $23.05M | +197.64% | 0.00% |
| CIG.C | -4.57% | $2.64B | +21.24% | 0.00% |
| DOGZ | -4.55% | $116.74M | -40.49% | 0.00% |
| AXON | -4.52% | $56.80B | +149.31% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBE | 47.51% | $233.59M | 0.58% |
| CALF | 47.05% | $4.28B | 0.59% |
| XPH | 46.92% | $155.51M | 0.35% |
| XSLV | 45.98% | $277.58M | 0.25% |
| RZV | 45.16% | $216.98M | 0.35% |
| XSHD | 44.52% | $75.91M | 0.3% |
| IJS | 44.34% | $6.38B | 0.18% |
| VIOV | 44.21% | $1.33B | 0.1% |
| DES | 44.19% | $1.90B | 0.38% |
| SLYV | 44.11% | $3.85B | 0.15% |
| RWJ | 44.10% | $1.58B | 0.39% |
| EES | 43.98% | $612.84M | 0.38% |
| PEY | 43.50% | $1.16B | 0.53% |
| VIOO | 43.45% | $2.94B | 0.1% |
| SMMV | 43.38% | $321.55M | 0.2% |
| XSVM | 43.29% | $593.31M | 0.37% |
| USVM | 43.27% | $979.42M | 0.3% |
| SYLD | 43.23% | $977.49M | 0.59% |
| IJR | 43.04% | $82.91B | 0.06% |
| SPSM | 42.79% | $11.90B | 0.03% |
